Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.52 |
| ▸ | JAK1 | P23458 | 11/20 | 0.41 |
| ▸ | JAK2 | O60674 | 10/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24538727 | 0.98 | BTK (0.51) | BTKJAK1JAK2MEN1KMT2A | |
| SCHEMBL27860905 | 0.97 | BTK (0.49) | BTKJAK1JAK2MEN1KMT2A | |
| SCHEMBL19191027 | 0.87 | BTK (0.41) | BTKJAK1JAK2TYK2 | |
| SCHEMBL18933321 | 0.84 | BTK (0.40) | BTKJAK1JAK2TYK2 | |
| SCHEMBL22108082 | 0.84 | BTK (0.40) | BTKJAK1JAK2TYK2 | |
| SCHEMBL12779158 | 0.84 | BTK (0.41) | BTKJAK1JAK2POLBTYK2 | |
| SCHEMBL27737650 | 0.83 | BTK (0.43) | BTKJAK1JAK2POLBTYK2 | |
| SCHEMBL28241591 | 0.82 | BTK (0.51) | BTKJAK1JAK2MEN1KMT2A | |
| SCHEMBL28240637 | 0.82 | BTK (0.51) | BTKJAK1JAK2MEN1KMT2A | |
| SCHEMBL18412893 | 0.82 | AADAT (0.40) | BTKJAK1JAK2TYK2AADAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022133420-A1 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
| CN-102292340-B | Amino-heterocyclic compounds used as pde9 inhibitors | PFIZER | 2015-05-06 | — | — | CN | disclosed |
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-14 | — | — | US | disclosed |
| CN-101448822-B | Substituted pyrazolopyrimidines | CEPHALON INC | 2013-11-06 | — | — | CN | disclosed |
| EP-2611809-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2024360-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES | CEPHALON INC (US) | 2013-04-03 | — | — | EP | disclosed |
| EP-2024360-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES | CEPHALON INC (US) | 2013-04-03 | — | — | EP | disclosed |
| US-8354414-B2 | Substituted bicyclic pyrimidines | CEPHALON, INC (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354414-B2 | Substituted bicyclic pyrimidines | CEPHALON, INC (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354414-B2 | Substituted bicyclic pyrimidines | CEPHALON, INC (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2024360-A2 | SUBSTITUTED PYRAZOLOPYRIMIDINES | Cephalon, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008063232-A2 | SUBSTITUTED PYRAZOLOPYRIMIDINES | CEPHALON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008063232-A2 | SUBSTITUTED PYRAZOLOPYRIMIDINES | CEPHALON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| EP-1534713-A1 | ALKYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | Bayer HealthCare AG (DE) | 2005-06-01 | — | — | EP | disclosed |
| EP-1534711-A1 | PHENYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | Bayer HealthCare AG (DE) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004026876-A1 | ALKYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004018474-A1 | PHENYL-SUBSTITUTED PYRAZOLOPYRIMIDINES | BAYER HEALTHCARE AG (DE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK3, JAK2, JAK1 | BTK 36/4885JAK1 3/4885JAK2 2/4885 |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | DPYD, P2RX5, P2RX6 | BTK 2145/4885JAK1 1084/4885JAK2 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.